Risk Evaluation and Mitigation Strategies (REMS) industry professionals are essential participants in moving the industry forward and bolstering patient safety and positive outcomes. Through research, innovation, and experience, REMS professionals contribute to advancing best practices in the development and regulation of new drugs and biologics. The REMS Industry Consortium (RIC) has dedicated this portion of the site to resources specifically tailored to REMS industry professionals. 

Return to this space for updated information as resources are developed for the exclusive use of RIC members.

FDA 7th Annual Drug Safety Priorities Report

The FDA recently published its 7th Annual Drug Safety Priorities Report with multiple references to REMS improvements and resources. 

RIC Introduction Letter

See the RIC’s letter of introduction to the FDA here. Share this update with contacts in your network to introduce RIC to your peers!